FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAkari Therapeutics, Plc
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AKTX
Akari Therapeutics, Plc Stock AnalysisComprehensive stock analysis for Akari Therapeutics, Plc (AKTX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAKTX
AKTX
Akari Therapeutics, Plc
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AKTX
  1. Home
  2. Stocks
  3. Akari Therapeutics, Plc

Akari Therapeutics, Plc

🇺🇸AKTX•NASDAQ

Akari Therapeutics, Plc

🇺🇸AKTX•NASDAQ
Market cap
$15.61M
Sentiment

Your view on AKTX

Mkt Cap
$15.61M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Akari Therapeutics, Plc

Industry
Biotechnology
Sector
Healthcare
CEO
Abizer Gaslightwala
Headquarters
75/76 Wimpole Street, London, GB
Industry
Biotechnology
Sector
Healthcare
CEO
Abizer Gaslightwala
Headquarters
75/76 Wimpole Street, London, GB
Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.

Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.

Akari Therapeutics, Plc is based in London, the United Kingdom.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Akari Therapeutics, Plc from FRC's valuation model, read against the market price. AKTX last traded at $6.80; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Akari Therapeutics, Plc. Starting points for Akari Therapeutics, Plc: EPS -$8.85, beta 1.47 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Akari Therapeutics, Plc. Akari Therapeutics, Plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Akari Therapeutics, Plc. Trailing twelve-month EPS for Akari Therapeutics, Plc stands at -$8.85. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 16, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$24.75

average of analysts' targets

 

$24.75

Low $19.50

Median $24.75

High $30.00

 

Analyst Ratings

Buy8 ratings
  • Strong Buy0
  • Buy7
  • Hold1
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate-$1.52-$2.09-$9.86-$5.49
Low estimate-$1.52-$2.09-$9.86-$5.49
High estimate-$1.52-$2.09-$9.86-$5.49
No. of analysts1111
Year-ago EPS-$2.991-$9.741-$20,800.001—
Growth————

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.00$0.00$9.58M$0.00
Low estimate$0.00$0.00$9.58M$0.00
High estimate$0.00$0.00$9.58M$0.00
No. of analysts0020
Year-ago revenue$0.00$0.00$0.00—
Growth————
Recent analyst actions15 rating and price-target changes, latest Sep 16, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from Benzinga; as of Nov 16, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Akari Therapeutics, Plc. Akari Therapeutics, Plc has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AKTX20 companies
Compare AKTX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • CDTCDT Equity Inc.Biotechnology$181,934
  • DRMADermata Therapeutics, Inc.Biotechnology$3M
  • MSPRMSP Recovery, Inc.Medical - Healthcare Information Services$1,377
  • PBMPsyence Biomedical Ltd.Biotechnology$59,815
  • PPBTPurple Biotech Ltd.Biotechnology$225,077
  • REVBRevelation Biosciences, Inc.Biotechnology$2M
  • SYRSSyros Pharmaceuticals, Inc.Biotechnology$21,464
  • VINCVincerx Pharma, Inc.Biotechnology$52,343

More Biotechnology companies

  • PTGXProtagonist Therapeutics, Inc.NASDAQ$8.5B
  • PTHSPelthos Therapeutics Inc.AMEX$29M
  • PTIXProtagenic Therapeutics, Inc.NASDAQ$470,654
  • PTNPalatin Technologies, Inc.NASDAQ$11M
  • PTX.AXPrescient Therapeutics LimitedASX
  • PULMPulmatrix, Inc.NASDAQ$5M
  • PVCTProvectus Biopharmaceuticals, Inc.OTC$19M
  • PVLAPalvella Therapeutics, Inc.NASDAQ$2.2B
  • PXMDPaxMedica, Inc. Common StockOTC$37,879
  • PXXLFPoxel S.A.OTC$13M
  • PYC.AXPYC Therapeutics LimitedASX
  • PYPDPolyPid Ltd.NASDAQ$127M
Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Akari Therapeutics, Plc, and how their positions are changing. At a $15.6M market value, institutional positions materially move Akari Therapeutics, Plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Akari Therapeutics, Plc executives and directors. Shares of Akari Therapeutics, Plc have traded between $0.47 and $1.73 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Akari Therapeutics, Plc. Coverage tracks Akari Therapeutics, Plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Akari Therapeutics, Plc.

AKTX Analysis
Fair
Past1
Growth2
Health5
Profit1
Value1

News

Latest Market News